RareResearch.AI
← Back to atlas

H323R

Category 3/4 — Most DruggablePathogenic/Likely pathogenicTransmembrane · predictedEditorial
HistidineArginine at position 323 · TM1 (314-334), helical transmembrane · WFS1 (Wolframin)

Histidine-to-arginine swap inside transmembrane helix TM1 — partial-charge histidine replaced by full-charge arginine in the bilayer environment, with mild predicted DeltaDeltaG that does not capture the membrane desolvation penalty.

Interactive 3D Structure

Wild-type reference
Wild-type H323 — hydrogen bond to P320
Fullscreen ↗
DynaMut2 mutant · H323R
Mutant R323 — energy-minimized; 2 new contacts formed
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost2 gained7 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondP320P320Preserved
Hydrogen bondA326A326Preserved
Hydrogen bondL327L327Preserved
Polar contactP320P320Preserved
Polar contactA326A326Preserved
Polar contactL327L327Preserved
Van der WaalsP320Gained
HydrophobicP320P320Preserved
HydrophobicL327Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.02kcal/mol
Destabilising — mild
AlphaMissense
0.687
LPath
AlphaFold pLDDT
77
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationPathogenic/Likely pathogenic
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsOptic atrophy
InheritanceInheritance pattern not explicitly recorded; ClinVar P/LP review provided.
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.968A>G
ClinVar accessionVCV000872210
Last evaluated2020/01/01 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Structural Context

H323 is held between His322 (2.45 Angstrom) and Ile324 (2.46 Angstrom) covalently. Through-space neighbors read Pro320 (3.53 Angstrom), Ala326 (4.25 Angstrom), Thr321 (4.49 Angstrom), Asn325 (4.49 Angstrom), and Leu327 (4.93 Angstrom). The pair of adjacent histidines at 322-323 is structurally distinctive: two imidazole side chains separated by a single peptide bond, both within a transmembrane helix. The wild-type arrangement likely places both imidazoles facing inward toward each other or coordinating with the polar Thr321 and Asn325, forming a small polar cluster within the helix interior.

Replacing H323 with arginine introduces a fully charged guanidinium where a partial-charge imidazole sat. The thermodynamic problem is desolvation: arginine in a bilayer interior carries a desolvation cost of 8-12 kcal/mol if fully buried, less if its side chain can snorkel toward an interfacial water network. The presence of nearby polar residues (Thr321, Asn325, the H322 imidazole) provides some partial solvation, but the local geometry was not built to host a permanently charged residue.

The structural consequence is one of two outcomes: either Arg323's guanidinium snorkels toward the cytoplasmic face of TM1 (potentially dragging the helix slightly out of register), or it remains buried at substantial energetic cost. Either outcome perturbs TM1 packing against its neighboring helices.

DynaMut2's DeltaDeltaG of -0.02 kcal/mol — essentially zero — is a known weakness of energy functions for buried charge substitutions. The function captures local van der Waals and hydrogen-bond changes but under-weights desolvation. AlphaMissense at 0.687 is closer to a true read of the disruption: clearly pathogenic (above the 0.564 threshold) but not the highest-scoring variant in this batch, consistent with the imidazole-to-guanidinium swap being chemically less drastic than e.g. a glycine-to-arginine substitution.

Amino-acid chemistry
Histidine (imidazole side chain, pKa ~6.0, mostly neutral at physiological pH but partially protonated) to Arginine (large, fully positively charged guanidinium, pKa ~12.5, ionized everywhere in physiological range) at position 323. The substitution converts a conditionally polar residue into a permanently charged one.
Position in the protein
Position 323 sits inside transmembrane helix TM1 (residues 314-334) — wolframin's first membrane-spanning segment, embedded in the ER bilayer. pLDDT 76.94 places the residue in an ordered region with confidence.

Druggability Assessment

Final classification: Category 3 — Most Druggable, with explicit caveats. The schema's strict DeltaDeltaG-magnitude rule places H323R in the small-perturbation bucket; the chemistry argues for a slightly more serious read. The variant is well-modeled (pLDDT 76.94), the AlphaMissense score is solidly pathogenic (0.687), and the lesion is localized. For druggability, the residue is buried in TM1 — accessible only via the bilayer or by a small molecule that engages the helix from the interfacial surface. Pharmacological chaperones that stabilize TM1 packing during co-translational membrane insertion are the most plausible therapeutic route. The clinical phenotype is currently limited to optic atrophy in ClinVar, which may reflect incomplete phenotypic ascertainment rather than tissue-specific penetrance.

Why this matters

H323R highlights the same TM-charge-burial issue as G437R: energy functions trained on soluble-protein mutations consistently under-read the cost of introducing a charged residue into a lipid bilayer. The Atlas should treat all such variants (any TM-resident histidine-to-arginine, glutamate-to-lysine, etc.) with an automatic structural-chemistry override flag. For wolframin specifically, mapping the TM-helix charged-residue substitutions is high-leverage. Each TM helix has a small number of residues whose substitution introduces or alters charge in the bilayer; these are systematically under-scored by DynaMut2 but well-flagged by AlphaMissense. The dual-metric framing the Atlas uses is exactly the right tool for catching them.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the H323R PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download H323R PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Transmembrane314334 · Helical